Excellent performance by new drugs at AstraZeneca led to 18% growth in the group’s sales, while the core operating profit grew by 8%, both outperforming the street as well as our expectations. Oncology continued to be at the forefront of this growth, supported by CVRM and respiratory. Top-line guidance for the year was upped, while core EPS guidance was maintained.